ALOX5 and colorectal carcinoma: In support of this, it has been demonstrated that using a dual combinatory inhibition with celecoxib and AA861, a specific 5-LOX inhibitor, displayed a better response than the use of each inhibitor individually in a CRC xenograft model, reducing side effects because of the use of lower doses [254].